Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Core Insights - Zevra Therapeutics, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million, expected to close within 30 to 45 days, subject to customary closing conditions [1][2] Financial Impact - The sale of the PRV will provide non-dilutive capital, strengthening the company's balance sheet with an addition of$150 million in gross cash proceeds [2] - This capital will support continued investment in strategic priorities, including the commercial launches of MIPLYFFA™ and OLPRUVA®, as well as advancing the pipeline of product candidates for rare diseases [2] Product and Regulatory Context - The PRV was granted to Zevra in September 2024 following the FDA approval of MIPLYFFA (arimoclomol), which is indicated for treating neurological manifestations of Niemann-Pick disease type C (NPC) in patients aged 2 years and older [2] - The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act (HSR) [2]